Dopamine-loaded poly (butyl cyanoacrylate) nanoparticles reverse behavioral deficits in Parkinson's animal models.

Aim: Parkinson's disease (PD) is a neurological disorder resulting from decreased dopamine (DA) secretion in the brain, which reflects impaired motor function. Thus, a drug-delivery system for releasing DA into the brain would be of crucial importance. Materials & methods: We herein examined the in vivo drug efficiency of novel poly-butyl-cyanoacrylate nanoparticles loaded with DA (DA-PBCA NPs). Results & conclusion: The NPs were able to pass through the blood-brain barrier and improve brain structure and function in the PD animal models. Moreover, we found a reduced α-synucleinopathy in the animal model brains after the NPs administration. Thus, the NPs seem to be a reliable DA delivery system for treating PD patients.

[1]  Hua Zheng,et al.  A bio-responsive 6-mercaptopurine/doxorubicin based "Click Chemistry" polymeric prodrug for cancer therapy. , 2020, Materials science & engineering. C, Materials for biological applications.

[2]  S. Seredenin,et al.  Chaperone Sigma1R mediates the neuroprotective action of afobazole in the 6-OHDA model of Parkinson’s disease , 2019, Scientific Reports.

[3]  Ana Margarida Araújo,et al.  A Metabolomic Approach for the In Vivo Study of Gold Nanospheres and Nanostars after a Single-Dose Intravenous Administration to Wistar Rats , 2019, Nanomaterials.

[4]  M. Hasegawa,et al.  Effect of L-DOPA/Benserazide on Propagation of Pathological α-Synuclein , 2019, Front. Neurosci..

[5]  T. Müller,et al.  Evaluating ADS5102 (amantadine) for the treatment of Parkinson’s disease patients with dyskinesia , 2019, Expert opinion on pharmacotherapy.

[6]  S. Naeem,et al.  Neuroprotective effect of diclofenac on chlorpromazine induced catalepsy in rats , 2019, Metabolic Brain Disease.

[7]  M. Nomoto,et al.  Behavioral tests predicting striatal dopamine level in a rat hemi-Parkinson's disease model , 2019, Neurochemistry International.

[8]  Daniel Weintraub,et al.  Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review , 2019, Movement disorders : official journal of the Movement Disorder Society.

[9]  Hua Zheng,et al.  Folate Receptor-Targeted and GSH-Responsive Carboxymethyl Chitosan Nanoparticles Containing Covalently Entrapped 6-Mercaptopurine for Enhanced Intracellular Drug Delivery in Leukemia , 2018, Marine drugs.

[10]  J. Miyasaki.  Parkinson’s Disease and Related Disorders , 2018, Neuropalliative Care.

[11]  B. Narasimhan,et al.  Treatment of neurodegenerative disorders through the blood-brain barrier using nanocarriers. , 2018, Nanoscale.

[12]  Roger M. Leblanc,et al.  Crossing the blood‐brain barrier with nanoparticles , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[13]  A. Najjar,et al.  Dopamine and Levodopa Prodrugs for the Treatment of Parkinson’s Disease , 2017, Molecules.

[14]  Hua Zheng,et al.  Synthesis and In Vitro Characterization of Carboxymethyl Chitosan-CBA-Doxorubicin Conjugate Nanoparticles as pH-Sensitive Drug Delivery Systems. , 2017, Journal of biomedical nanotechnology.

[15]  T. Walz,et al.  Discovery and characterization of stable and toxic Tau/phospholipid oligomeric complexes , 2017, Nature Communications.

[16]  R. A. Wheeler,et al.  Corticosterone regulates both naturally occurring and cocaine‐induced dopamine signaling by selectively decreasing dopamine uptake , 2017, The European journal of neuroscience.

[17]  K. Seppi,et al.  Magnetic resonance imaging for the diagnosis of Parkinson’s disease , 2017, Journal of Neural Transmission.

[18]  Weiyun Wang,et al.  Optimization of paeonol‐loaded poly(butyl‐2‐cyanoacrylate) nanocapsules by central composite design with response surface methodology together with the antibacterial properties , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[19]  Dongan Wang,et al.  Novel Gelatin-based Nano-gels with Coordination-induced Drug Loading for Intracellular Delivery , 2016 .

[20]  G. Rizzo,et al.  Brain MR Contribution to the Differential Diagnosis of Parkinsonian Syndromes: An Update , 2016, Parkinson's disease.

[21]  Raquel Ferreira,et al.  Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[22]  R. Reul,et al.  Development and lyophilization of itraconazole loaded poly(butylcyanoacrylate) nanospheres as a drug delivery system. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[23]  D. Quintanar-Guerrero,et al.  Nanoparticle technology for treatment of Parkinson's disease: the role of surface phenomena in reaching the brain. , 2015, Drug discovery today.

[24]  E. Rashed,et al.  Potential efficacy of dopamine loaded-PVP/PAA nanogel in experimental models of Parkinsonism: possible disease modifying activity. , 2015, Journal of biomedical materials research. Part A.

[25]  Rajendra Kumar Shukla,et al.  Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats. , 2015, ACS nano.

[26]  J. Brotchie,et al.  The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease , 2013, Pharmacological Reviews.

[27]  Luigia Sabbatini,et al.  Dopamine-loaded chitosan nanoparticles: formulation and analytical characterization , 2011, Analytical and bioanalytical chemistry.

[28]  Yong Huang,et al.  Synthesis, self-assembly and drug release behaviors of pH-responsive copolymers ethyl cellulose-graft-PDEAEMA through ATRP , 2011 .

[29]  G. Sobue,et al.  Putaminal magnetic resonance imaging features at various magnetic field strengths in multiple system atrophy , 2010, Movement disorders : official journal of the Movement Disorder Society.

[30]  H. von Briesen,et al.  Adsorption of obidoxime onto human serum albumin nanoparticles: Drug loading, particle size and drug release , 2010, Journal of microencapsulation.

[31]  M. Schocke,et al.  Significance of MRI in Diagnosis and Differential Diagnosis of Parkinson’s Disease , 2010, Neurodegenerative Diseases.

[32]  V. Pillay,et al.  Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain. , 2009, International journal of pharmaceutics.

[33]  A. Hartmann,et al.  Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and α-synuclein-deleted mice , 2008, Experimental Neurology.

[34]  Tycho Heimbach,et al.  Prodrugs: design and clinical applications , 2008, Nature Reviews Drug Discovery.

[35]  K. Kisich,et al.  Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis. , 2007, International journal of pharmaceutics.

[36]  Chi-Yu Huang,et al.  Synthesis of high loading and encapsulation efficient paclitaxel-loaded poly(n-butyl cyanoacrylate) nanoparticles via miniemulsion. , 2007, International journal of pharmaceutics.

[37]  M. R. Kumar,et al.  PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[38]  J. González-Mora,et al.  Nigrostriatal cell firing action on the dopamine transporter , 2007, The European journal of neuroscience.

[39]  M. Michaelis,et al.  Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors , 2007, Journal of Molecular Neuroscience.

[40]  H. Khan,et al.  Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats , 2005, Brain Research Bulletin.

[41]  D. Begley,et al.  Direct Evidence That Polysorbate-80-Coated Poly(Butylcyanoacrylate) Nanoparticles Deliver Drugs to the CNS via Specific Mechanisms Requiring Prior Binding of Drug to the Nanoparticles , 2003, Pharmaceutical Research.

[42]  D. A. Kharkevich,et al.  Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles , 1997, Pharmaceutical Research.

[43]  S. Amara,et al.  Dynamic regulation of the dopamine transporter. , 2003, European journal of pharmacology.

[44]  Timothy Schallert,et al.  Brain-dependent movements and cerebral-spinal connections: key targets of cellular and behavioral enrichment in CNS injury models. , 2003, Journal of rehabilitation research and development.

[45]  D. A. Kharkevich,et al.  Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. , 1998, Journal of microencapsulation.

[46]  Rainer H. Müller,et al.  Alkylcyanoacrylate drug carriers: II. Cytotoxicity of cyanoacrylate nanoparticles with different alkyl chain length , 1992 .